

# Zhi-Gang She

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2108666/publications.pdf>

Version: 2024-02-01

79  
papers

6,587  
citations

147801

31  
h-index

71685

76  
g-index

80  
all docs

80  
docs citations

80  
times ranked

11437  
citing authors

#	ARTICLE	IF	CITATIONS
1	A conventional immune regulator mitochondrial antiviral signaling protein blocks hepatic steatosis by maintaining mitochondrial homeostasis. <i>Hepatology</i> , 2022, 75, 403-418.	7.3	15
2	NAFLD as a continuous driver in the whole spectrum of vascular disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 163, 118-132.	1.9	17
3	Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. <i>Journal of Infection and Public Health</i> , 2022, 15, 13-20.	4.1	30
4	The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis. <i>Frontiers in Endocrinology</i> , 2022, 13, 812610.	3.5	14
5	High Remnant Cholesterol Level Potentiates the Development of Hypertension. <i>Frontiers in Endocrinology</i> , 2022, 13, 830347.	3.5	20
6	Projection of global burden and risk factors for aortic aneurysm – timely warning for greater emphasis on managing blood pressure. <i>Annals of Medicine</i> , 2022, 54, 553-564.	3.8	16
7	Global death burden and attributable risk factors of peripheral artery disease by age, sex, SDI regions, and countries from 1990 to 2030: Results from the Global Burden of Disease study 2019. <i>Atherosclerosis</i> , 2022, 347, 17-27.	0.8	7
8	Distributions and trends of the global burden of COPD attributable to risk factors by SDI, age, and sex from 1990 to 2019: a systematic analysis of GBD 2019 data. <i>Respiratory Research</i> , 2022, 23, 90.	3.6	33
9	The E3 Ligase TRIM16 Is a Key Suppressor of Pathological Cardiac Hypertrophy. <i>Circulation Research</i> , 2022, 130, 1586-1600.	4.5	21
10	Association Between Lipid Profiles and Left Ventricular Hypertrophy: New Evidence from a Retrospective Study. <i>Chinese Medical Sciences Journal</i> , 2022, 37, 103.	0.4	3
11	Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C630-C639.	4.6	10
12	Impact of NAFLD and its pharmacotherapy on lipid profile and CVD. <i>Atherosclerosis</i> , 2022, 355, 30-44.	0.8	7
13	Milk Fat Globule – Epidermal Growth Factor – Factor 8 Improves Hepatic Steatosis and Inflammation. <i>Hepatology</i> , 2021, 73, 586-605.	7.3	27
14	Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta – Activated Kinase 1 – c-Jun – N-Terminal Kinase/p38 Signaling. <i>Hepatology</i> , 2021, 73, 104-125.	7.3	40
15	Kidney Function Indicators Predict Adverse Outcomes of COVID-19. <i>Med</i> , 2021, 2, 38-48.e2.	4.4	47
16	The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19. <i>Cell Metabolism</i> , 2021, 33, 258-269.e3.	16.2	87
17	Development and validation of a risk score using complete blood count to predict in-hospital mortality in COVID-19 patients. <i>Med</i> , 2021, 2, 435-447.e4.	4.4	20
18	A risk score based on baseline risk factors for predicting mortality in COVID-19 patients. <i>Current Medical Research and Opinion</i> , 2021, 37, 917-927.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia. <i>Circulation Research</i> , 2021, 128, 1747-1765.	4.5	49
20	A kinome screen reveals that Nemo-like kinase is a key suppressor of hepatic gluconeogenesis. <i>Cell Metabolism</i> , 2021, 33, 1171-1186.e9.	16.2	10
21	TMBIM1 is an inhibitor of adipogenesis and its depletion promotes adipocyte hyperplasia and improves obesity-related metabolic disease. <i>Cell Metabolism</i> , 2021, 33, 1640-1654.e8.	16.2	22
22	Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD. <i>Hepatology</i> , 2021, 74, 1319-1338.	7.3	11
23	Therapeutic Potential of G Protein-Coupled Receptors Against Nonalcoholic Steatohepatitis. <i>Hepatology</i> , 2021, 74, 2831-2838.	7.3	10
24	Pharmacological inhibition of arachidonate 12-lipoxygenase ameliorates myocardial ischemia-reperfusion injury in multiple species. <i>Cell Metabolism</i> , 2021, 33, 2059-2075.e10.	16.2	35
25	Global Burden of Disease Study 2019 suggests that metabolic risk factors are the leading drivers of the burden of ischemic heart disease. <i>Cell Metabolism</i> , 2021, 33, 1943-1956.e2.	16.2	59
26	Newly-Diagnosed Diabetes and Sustained Hyperglycemia are Associated with Poorer Outcomes in COVID-19 Inpatients Without Pre-Existing Diabetes. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021, Volume 14, 4469-4482.	2.4	5
27	A small molecule targeting ALOX12-ACC1 ameliorates nonalcoholic steatohepatitis in mice and macaques. <i>Science Translational Medicine</i> , 2021, 13, eabg8116.	12.4	30
28	Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis. <i>Science Translational Medicine</i> , 2021, 13, eabg8117.	12.4	23
29	Heavy Disease Burden of High Systolic Blood Pressure During 1990-2019: Highlighting Regional, Sex, and Age Specific Strategies in Blood Pressure Control. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 754778.	2.4	14
30	Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1. <i>Hepatology</i> , 2020, 71, 93-111.	7.3	55
31	Nonalcoholic Fatty Liver Disease. <i>Hypertension</i> , 2020, 75, 275-284.	2.7	121
32	Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 32, 537-547.e3.	16.2	116
33	Ca <sup>2+</sup> -Dependent NOX5 (NADPH Oxidase 5) Exaggerates Cardiac Hypertrophy Through Reactive Oxygen Species Production. <i>Hypertension</i> , 2020, 76, 827-838.	2.7	42
34	Redefining Cardiac Biomarkers in Predicting Mortality of Inpatients With COVID-19. <i>Hypertension</i> , 2020, 76, 1104-1112.	2.7	118
35	STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy. <i>Hypertension</i> , 2020, 76, 1219-1230.	2.7	23
36	Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 892-908.e11.	16.2	92

#	ARTICLE	IF	CITATIONS
37	In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. <i>Cell Metabolism</i> , 2020, 32, 176-187.e4.	16.2	400
38	Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. <i>Circulation Research</i> , 2020, 126, 679-704.	4.5	121
39	Epidemiological Features of NAFLD From 1999 to 2018 in China. <i>Hepatology</i> , 2020, 71, 1851-1864.	7.3	341
40	CARD3 Promotes Cerebral Ischemiaâ€Reperfusion Injury Via Activation of TAK1. <i>Journal of the American Heart Association</i> , 2020, 9, e014920.	3.7	14
41	Longitudinal Association Between Markers of Liver Injury and Mortality in COVIDâ€19 in China. <i>Hepatology</i> , 2020, 72, 389-398.	7.3	346
42	Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. <i>Cell Metabolism</i> , 2020, 31, 1068-1077.e3.	16.2	1,207
43	TNFAIP3 Interacting Protein 3 Overexpression Suppresses Nonalcoholic Steatohepatitis by Blocking TAK1 Activation. <i>Cell Metabolism</i> , 2020, 31, 726-740.e8.	16.2	60
44	Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. <i>Circulation Research</i> , 2020, 126, 1671-1681.	4.5	948
45	Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis. <i>Clinical Science</i> , 2020, 134, 1775-1799.	4.3	25
46	No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. <i>World Journal of Clinical Cases</i> , 2020, 8, 5576-5588.	0.8	26
47	Sophoricoside ameliorates cardiac hypertrophy by activating AMPK/mTORC1-mediated autophagy. <i>Bioscience Reports</i> , 2020, 40, .	2.4	7
48	Reply:. <i>Hepatology</i> , 2019, 70, 2239-2240.	7.3	0
49	Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. <i>Gene Expression</i> , 2019, 19, 187-198.	1.2	23
50	Fâ€box/WD Repeatâ€Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signalâ€Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice. <i>Hepatology</i> , 2019, 70, 1942-1957.	7.3	36
51	Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Metaâ€Analysis. <i>Hepatology</i> , 2019, 70, 1119-1133.	7.3	355
52	Integrated Omics Reveals Tollip as an Regulator and Therapeutic Target for Hepatic Ischemiaâ€Reperfusion Injury in Mice. <i>Hepatology</i> , 2019, 70, 1750-1769.	7.3	44
53	Tumor-specific macrophage targeting through recognition of retinoid X receptor beta. <i>Journal of Controlled Release</i> , 2019, 301, 42-53.	9.9	36
54	Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. <i>World Journal of Gastroenterology</i> , 2019, 25, 1307-1326.	3.3	146

#	ARTICLE	IF	CITATIONS
55	Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor $\beta$ in Mice. <i>Hepatology</i> , 2019, 69, 2471-2488.	7.3	37
56	Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. <i>Gene Expression</i> , 2019, 19, 175-185.	1.2	20
57	Tumor Progression Locus 2 in Hepatocytes Potentiates Both Liver and Systemic Metabolic Disorders in Mice. <i>Hepatology</i> , 2019, 69, 524-544.	7.3	14
58	Reduced atherosclerosis lesion size, inflammatory response in miR-150 knockout mice via macrophage effects. <i>Journal of Lipid Research</i> , 2018, 59, 658-669.	4.2	22
59	Time to step up the fight against NAFLD. <i>Hepatology</i> , 2018, 67, 2068-2071.	7.3	29
60	The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis. <i>Nature Medicine</i> , 2018, 24, 213-223.	30.7	104
61	Mindin deficiency in macrophages protects against foam cell formation and atherosclerosis by targeting LXR $\beta$ . <i>Clinical Science</i> , 2018, 132, 1199-1213.	4.3	12
62	An ALOX12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. <i>Nature Medicine</i> , 2018, 24, 73-83.	30.7	155
63	The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis. <i>Nature Medicine</i> , 2018, 24, 84-94.	30.7	145
64	Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy. <i>Circulation</i> , 2018, 137, 1486-1504.	1.6	32
65	Carboxyl-Terminal Modulator Protein Ameliorates Pathological Cardiac Hypertrophy by Suppressing the Protein Kinase B Signaling Pathway. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	5
66	Wang et al. reply. <i>Nature Medicine</i> , 2018, 24, 700-701.	30.7	3
67	Ablation of Interferon Regulatory Factor 3 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Hypertension</i> , 2017, 69, 510-520.	2.7	24
68	Dickkopf3 Ablation Attenuates the Development of Atherosclerosis in ApoE-Deficient Mice. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	28
69	Vinexin $\beta$ Ablation Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice by Inactivating the Akt-Nuclear Factor $\kappa$ B Inflammatory Axis. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	13
70	Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates. <i>Nature Medicine</i> , 2017, 23, 439-449.	30.7	183
71	Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4. <i>Nature Medicine</i> , 2017, 23, 742-752.	30.7	113
72	The Paraoxonase Gene Cluster Protects Against Abdominal Aortic Aneurysm Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 291-300.	2.4	16

#	ARTICLE	IF	CITATIONS
73	Interferon Regulatory Factor 4 Inhibits Neointima Formation by Engaging KrÄppel-Like Factor 4 Signaling. <i>Circulation</i> , 2017, 136, 1412-1433.	1.6	33
74	Restoration of Circulating MFGE8 (Milk Fat Globule-EGF Factor 8) Attenuates Cardiac Hypertrophy Through Inhibition of Akt Pathway. <i>Hypertension</i> , 2017, 70, 770-779.	2.7	37
75	LILRB4 deficiency aggravates the development of atherosclerosis and plaque instability by increasing the macrophage inflammatory response via NF-Î¸B signaling. <i>Clinical Science</i> , 2017, 131, 2275-2288.	4.3	24
76	USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity. <i>Hepatology</i> , 2017, 66, 1866-1884.	7.3	48
77	The Ubiquitin E3 Ligase TRAF6 Exacerbates Ischemic Stroke by Ubiquitinating and Activating Rac1. <i>Journal of Neuroscience</i> , 2017, 37, 12123-12140.	3.6	55
78	Loss of Caspase-Activated DNase Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	7
79	NG2 Proteoglycan Ablation Reduces Foam Cell Formation and Atherogenesis via Decreased Low-Density Lipoprotein Retention by Synthetic Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 49-59.	2.4	17